Tredegar Corporation (TREDEGAR CORP) - 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for the period ended March 31, 2001. Tredegar Corporation operates in three primary segments: Film Products, Aluminum Extrusions, and Biotechnology operations (Molecumetics and Therics), alongside a significant Venture Capital investment portfolio (Tredegar Investments). The company is headquartered in Richmond, Virginia.
Key Financial Metrics
| Metric | Q1 2001 | Q1 2000 |
|---|---|---|
| Net Sales | $191.8 million | $232.2 million |
| Net Income | $1.9 million | $18.5 million |
| Earnings Per Share (Diluted) | $0.05 | $0.47 |
| Gross Profit Margin | 18.2% | 19.7% |
| Operating Cash Flow | $14.4 million | $23.6 million |
| Cash and Equivalents (End of Period) | $46.1 million | $13.7 million |
| Long-Term Debt | $269.5 million | $268.1 million |
| Venture Capital NAV | $296.5 million | $276.7 million |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 17% year-over-year, driven by a 28.5% volume drop in Aluminum Extrusions and a 12.7% volume drop in Film Products.
- Profitability Collapse: Net income fell 89.7% to $1.9 million. This was primarily due to a $5.3 million after-tax loss from venture capital investments (compared to a $7.8 million gain in 2000) and a $1 million charge for film business reorganization.
- Segment Performance:
- Aluminum Extrusions: Operating profit plummeted 59% to $6.4 million due to lower demand in transportation/construction and higher energy costs.
- Film Products: Operating profit (excluding unusual items) declined 4.2% to $15.1 million, partially offset by higher-margin new products.
- Biotechnology: Operating losses widened to $4.1 million due to increased R&D spending at Molecumetics and Therics.
- Venture Capital Volatility: The Net Asset Value (NAV) of venture investments depreciated by $36.1 million after-tax, largely due to stock price declines in public holdings (e.g., Illumina, Rosetta Inpharmatics) and lower valuations of private companies.
Guidance, Outlook, and Risks
Management Commentary: Management notes that Q1 2001 results are not necessarily indicative of full-year expectations. The company adopted a new accounting standard for derivative instruments (FAS 133) on January 1, 2001, resulting in a cumulative-effect adjustment to equity but no impact on earnings. An interest rate swap was entered into in April 2001 to hedge $50 million of variable-rate debt.
Key Risks and Contingencies:
- Customer Concentration: Film Products is heavily dependent on Procter & Gamble (P&G), which accounted for 64% of segment sales in 2000. Loss of this customer would be material.
- Cyclical Markets: Aluminum Extrusions are highly sensitive to economic cycles and seasonal slowdowns, with high operating leverage exacerbating profit declines during downturns.
- Venture Capital Risk: The portfolio faces risks of business failure, illiquidity, and market volatility. Valuation of private holdings is subjective.
- Biotech Uncertainty: Biotechnology operations have incurred losses since inception with no assurance of future profitability or regulatory approval.
Investor Verification Checklist
- Venture Capital Valuation: Verify the methodology used to value private company holdings, given the $36.1 million NAV depreciation and the subjective nature of these valuations.
- P&G Dependency: Assess the stability of the relationship with Procter & Gamble and the progress of efforts to diversify the Film Products customer base.
- Aluminum Cost Pass-Through: Monitor the company's ability to pass higher aluminum ingot and energy costs to customers in a competitive, cyclical market.
- Biotech Burn Rate: Review the timeline and funding requirements for Molecumetics and Therics to reach commercialization, as they continue to generate significant operating losses.
- Derivative Accounting: Confirm the impact of the new FAS 133 standard on future earnings volatility regarding aluminum price hedging.